TY - JOUR
T1 - Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
AU - Astrup, Arne
AU - Madsbad, Sten
AU - Breum, Leif
AU - Jensen, Thomas J
AU - Kroustrup, Jens Peter
AU - Larsen, Thomas Meinert
PY - 2008
Y1 - 2008
N2 - BACKGROUND: Weight-loss drugs produce an additional mean weight loss of only 3-5 kg above that of diet and placebo over 6 months, and more effective pharmacotherapy of obesity is needed. We assessed the efficacy and safety of tesofensine-an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin-in patients with obesity. METHODS: We undertook a phase II, randomised, double-blind, placebo-controlled trial in five Danish obesity management centres. After a 2 week run-in phase, 203 obese patients (body-mass index 30-
AB - BACKGROUND: Weight-loss drugs produce an additional mean weight loss of only 3-5 kg above that of diet and placebo over 6 months, and more effective pharmacotherapy of obesity is needed. We assessed the efficacy and safety of tesofensine-an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin-in patients with obesity. METHODS: We undertook a phase II, randomised, double-blind, placebo-controlled trial in five Danish obesity management centres. After a 2 week run-in phase, 203 obese patients (body-mass index 30-
U2 - http://dx.doi.org/10.1016/S0140-6736(08)61525-1
DO - http://dx.doi.org/10.1016/S0140-6736(08)61525-1
M3 - Journal article
SN - 0140-6736
VL - 372
SP - 1906
EP - 1913
JO - Lancet
JF - Lancet
IS - 9653
ER -
